Blackstone Inc vs Sana Biotechnology Inc — how do they compare? Blackstone Inc trades at $129.51 (market cap $152.15B), while Sana Biotechnology Inc trades at $3.52 (market cap $994.89M). The key difference: Blackstone Inc is far larger — about 152.9× Sana Biotechnology Inc's market cap, and Blackstone Inc pays a 3.99% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BX | SANA | |
|---|---|---|
Market Cap | $152.15B | $994.89M |
Sector | Financials | Health |
52-Week High | $188.68 | $5.92 |
52-Week Low | $102.12 | $2.68 |
Dividend Yield | 3.99% | — |
Enterprise Value | — | $969.08M |
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.
Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Trailing returns across standard periods
Latest headlines on both assets
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →